𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Juvenile chronic myeloid leukaemia and alpha-interferon

✍ Scribed by M. Aricò; L. Nespoli; D. Caselli; F. Bonetti; F. A. Porta; G. R. Burgio

Publisher
Springer
Year
1989
Tongue
English
Weight
173 KB
Volume
148
Category
Article
ISSN
0340-6997

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Therapeutic targets in chronic myeloid l
Therapeutic targets in chronic myeloid leukaemia
✍ Nicholas B. Heaney; Tessa L. Holyoake 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 162 KB

## Abstract Chronic myeloid leukaemia (CML) is a clonal disorder of the haemopoietic stem cell arising as a consequence of the formation of the __bcr‐abl__ oncogene. The particular molecular basis of this condition has enabled the development of therapies that selectively target diseased cells. The

Congenital juvenile chronic myelogenous
Congenital juvenile chronic myelogenous leukemia: Therapeutic trial with interferon alpha-2
✍ Hazani, Anna ;Barak, Yigal ;Berant, Moshe ;Bar-Maor, Adoniram 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 406 KB

## Abstract A newborn with congenital juvenile chronic myelogenous leukemia (JCML) is described. The diagnosis was suggested by the characteristic clinical and hematologic presentation, and was confirmed by the results of in‐vitro cultures of the hematopoietic progenitors, which showed excessive pr

Recurrent annular erythema in juvenile c
Recurrent annular erythema in juvenile chronic myelogenous leukaemia
✍ Anzai; Kikuchi; Kinoshita; Nishikawa 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 357 KB

Juvenile chronic myelogenous leukaemia (JCML) is a rare haematological malignancy of myelomonocytic lineage that affects patients less than 4 years of age and is known as an entity different from adult-type chronic myelogenous leukaemia. In JCML, skin manifestations are relatively common but most of

Response to the combined administration
Response to the combined administration of interferons alpha and gamma after failure of single interferon therapy in chronic myelogenous leukaemia
✍ Kloke, Otto ;Becher, Reinhard ;Niederle, Norbert 📂 Article 📅 1987 🏛 Springer-Verlag ⚖ 332 KB

A previously untreated patient with benign phase chronic myelogenous leukaemia (CML) was treated with recombinant Interferon alpha-2b. Haematological remission was induced for a total of twelve months. Thereafter, the patient developed resistance to Interferon alpha manifested by an increase in leuc